Sun.Feb 25, 2024

article thumbnail

Rare Disease Day 2024 – The importance of shining a light on rare diseases

pharmaphorum

Rare Disease Day 2024 is an important opportunity to raise awareness about rare diseases and the need for research, diagnosis, and treatment options like orphan drugs. Learn the significance of shining a light on rare diseases.

Drugs 118
article thumbnail

CymaBay's seladelpar has the potential to raise the bar in treatment for PBC

Outsourcing Pharma

Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and supports the potential for seladelpar to raise the bar in treatment of the disease.

Trials 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Which pharmaceutical companies have the most drug patents in Serbia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 104
article thumbnail

Interchangeable high-concentration Humira approved in US

pharmaphorum

TevaU and Alvotech claim first US approval for first biosimilar of AbbVie’s high-concentration Humira, which accounts for 88% of brand prescriptions

Branding 108
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Post?COVID-19 Kidney Outcomes

JAMA Internal Medicine

This cohort study assesses long-term kidney outcomes among hospitalized patients with COVID-19−associated acute kidney injury.

81
article thumbnail

New patent expiration for Endo Pharms drug NASCOBAL

Drug Patent Watch

Annual Drug Patent Expirations for NASCOBAL Nascobal is a drug marketed by Par Pharm and Endo Pharms Inc and is included in two NDAs. It is available from one supplier.… The post New patent expiration for Endo Pharms drug NASCOBAL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59

More Trending

article thumbnail

New patent expiration for Almatica drug GRALISE

Drug Patent Watch

Annual Drug Patent Expirations for GRALISE Gralise is a drug marketed by Almatica and is included in one NDA. It is available from one supplier. There is one patent protecting… The post New patent expiration for Almatica drug GRALISE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

Health Canada disclosing more information on pending generic drug submissions

Pharma in Brief

On February 23, 2024, Health Canada published a Notice advising that it was making its review process for generic drug submissions more transparent. Specifically, for generic drug submissions accepted into review on or after April 1, 2024, Health Canada will start disclosing: (i) the year and month that the submission was accepted for review; and (ii) the company sponsoring the generic drug.

article thumbnail

Individualizing Care for Older Adults With Diabetes Amid the Revolution in Pharmacotherapy

JAMA Internal Medicine

This JAMA Network Insights reassesses the approach to caring for older adults with diabetes in the context of newly available pharmacologic agents.

51